This Study Will Evaluate the Effect of Canakinumab or Pembrolizumab Given as Monotherapy or in Combination as Neo-adjuvant Treatment for Subjects With Early Stages NSCLC.

Official Title

A Randomized, Open-label, Phase II Study of Canakinumab or Pembrolizumab as Monotherapy or in Combination as Neoadjuvant Therapy in Subjects With Resectable Non-small Cell Lung Cancer (CANOPY-N)


Major pathological response (MPR) rate of canakinumab given as a neoadjuvant treatment, either as single agent or in combination with pembrolizumab, in addition to evaluate the MPR rate of pembrolizumab as a single agent. Additionally the dynamics of the tumour microenvironment changes on treatment by comparing pre-, on- and post-treatment samples will be evaluated.

Trial Description

Primary Outcome:

  • Major Pathological Response (MPR) rate based on Central review
Secondary Outcome:
  • Antidrug antibodies (ADA) of canakinumab
  • Antidrug antibodies (ADA) of pembrolizumab
  • Overall response rate (ORR) per investigator assessment using RECIST v1.1
  • Serum canakinumab concentration
  • Serum pembrolizumab concentration
  • Surgical feasibility rate
  • MPR based on central review
  • MPR based on local review
  • Difference in MPR rate based on central review
  • MPR rate based on the levels of biomarkers

View this trial on

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.


Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society